Impact BioMedical

IBO

時価総額 $2290万

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley's Bio Labs Limited) (“Zoar Labs”), which includes Impact's preliminary proxy statement. The F-4 Registration Statement is available through the SEC's website at www.sec.gov under the name “Zoar Limited”.

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split. No other changes have been made to the original press release.

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company's Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Impact Biomedical Inc. (NYSE American: IBO) resulting from allegations that Impact Biomedical may have issued materially misleading business information to the investing public. So what: If you purchased Impact Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Impact Biomedical Inc. (NYSE American: IBO) resulting from allegations that Impact Biomedical may have issued materially misleading business information to the investing public. So what: If you purchased Impact Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a.

HOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025.

HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO's 3F™ technology platform.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Impact BioMedical Inc. (NYSE American: IBO) and Dr Ashleys Limited is fair to Impact shareholders. Halper Sadeh encourages Impact shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Impact and its board violated.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share exchange agreement (the “Merger Agreement”) on June 21, 2025 to enter into a strategic merger transaction (the “Transaction”). Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity (the “PubCo”) traded on the NYSE American under the name “Dr Ashleys Limited.”

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.